Spinal and Bulbar Muscular Atrophy Clinical Trial
Official title:
A Placebo-controlled Study to Evaluate the Efficacy and Safety of Clenbuterol in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)
There is no cure to arrest or delay SBMA progression. It is estimated that ~1000 individuals are affected by SBMA in Italy at any given time (prevalence: 1.5/100000) with an annual incidence of 0.19/100000 males. Here, we are going to test the potential of beta2-agonist stimulation on muscle as a therapeutic avenue for SBMA. We have provided pre-clinical evidence that β-agonist stimulation may be a therapeutic strategy for SBMA. Moreover, we have shown that beta2-agonists are effective in improving motor function without relevant adverse events in a small cohort of SBMA patients. To establish safety and efficacy of clenbuterol as a cure for SBMA, we are conducting a multicenter, phase II, randomized, double-blind, parallel-group, single dose, placebo-controlled trial. Indeed, based on our preliminary data, some concerns remain to be addressed.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04944940 -
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
|
||
Recruiting |
NCT03555578 -
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
|
||
Completed |
NCT00303446 -
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)
|
Phase 2 | |
Recruiting |
NCT06411912 -
A Study of NIDO-361 in Patients With SBMA
|
Phase 2 | |
Completed |
NCT02156141 -
High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy
|
N/A | |
Completed |
NCT02024932 -
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
|
Phase 2 | |
Active, not recruiting |
NCT05517603 -
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
|
Phase 1/Phase 2 |